신경변성 치료제 시장 : 세계 예측(2026-2032년)

The Neurodegenerative Drugs Market is projected to grow by USD 81.51 billion at a CAGR of 7.92% by 2032.

Executive Introduction to Neurodegenerative Drugs

Neurodegenerative drugs are entering a pivotal phase as rising disease burden, aging populations, improved diagnostic pathways, and advances in disease biology reshape therapeutic priorities across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis-related neurodegeneration, and rare inherited neurological disorders. The World Health Organization recognizes neurological disorders as a major contributor to disability worldwide, while dementia and Parkinson's disease are increasingly prioritized in national aging and brain health strategies. The sector is shifting from predominantly symptomatic treatment toward disease-modifying strategies that target amyloid, tau, alpha-synuclein, neuroinflammation, mitochondrial dysfunction, lysosomal pathways, synaptic loss, and genetic drivers. Regulatory agencies have increasingly emphasized biomarker-supported development, real-world evidence, patient-centered endpoints, and post-approval monitoring, reflecting both the promise and complexity of therapies intended to alter disease trajectories.

Clinical and commercial momentum is being shaped by the need for earlier diagnosis, scalable biomarker testing, equitable access to specialty care, and robust pharmacovigilance. Cerebrospinal fluid assays, amyloid and tau PET imaging, plasma-based biomarkers, digital cognitive assessments, and genetic testing are helping identify patients earlier and refine trial enrollment. At the same time, safety monitoring requirements, infusion capacity, payer scrutiny, and caregiver burden remain critical adoption barriers. For stakeholders across pharmaceutical development, healthcare delivery, reimbursement, and public health, neurodegenerative drugs represent a high-priority therapeutic field where scientific progress must be matched by operational readiness and evidence generation.

Transformative Shifts in the Neurodegenerative Drugs Landscape

The neurodegenerative drugs landscape is being transformed by a move toward precision neurology, biomarker-defined populations, and mechanism-based treatment design. Alzheimer's disease development has accelerated interest in anti-amyloid and anti-tau approaches, while Parkinson's disease programs increasingly investigate alpha-synuclein aggregation, glucocerebrosidase-related biology, neuroinflammation, and dopaminergic neuroprotection. In ALS and rare neurogenetic disorders, antisense oligonucleotides, gene-targeted therapies, RNA modulation, and mutation-specific approaches are reshaping clinical strategy by linking treatment selection to molecular diagnosis.

Another major shift is the expansion of trial endpoints beyond traditional clinical scales. Sponsors and investigators are increasingly incorporating fluid biomarkers, imaging outcomes, digital motor measures, speech analytics, wearables, remote cognitive testing, and patient-reported outcomes to detect progression earlier and reduce variability. Decentralized and hybrid trial models are also gaining importance because neurodegenerative diseases often limit patient mobility and impose substantial caregiver demands. Meanwhile, regulatory frameworks are evolving to balance accelerated access with evidence requirements, especially where biomarker changes are considered reasonably likely to predict clinical benefit.

Healthcare systems are also undergoing structural change. Disease-modifying therapies often require early diagnosis, specialist confirmation, baseline imaging or laboratory assessment, infusion or complex administration pathways, and longitudinal safety surveillance. This is driving greater integration among neurologists, memory clinics, radiology networks, genetic counselors, primary care providers, specialty pharmacies, and patient advocacy organizations. The most successful ecosystem participants are those aligning scientific innovation with diagnosis capacity, reimbursement evidence, treatment monitoring, and equitable patient navigation.

Cumulative Impact of Artificial Intelligence on Neurodegenerative Drugs

Artificial intelligence is becoming a cumulative force across neurodegenerative drug discovery, clinical development, diagnosis, and treatment monitoring. In early research, AI-enabled platforms support target identification by analyzing genomics, proteomics, transcriptomics, imaging, pathology, and longitudinal clinical datasets. Machine learning models can help prioritize molecular pathways involved in protein misfolding, neuroinflammation, synaptic dysfunction, and neuronal loss, while computational chemistry and generative modeling are being used to screen compounds, optimize binding properties, and improve central nervous system drug-likeness.

In clinical development, AI is strengthening patient stratification and trial design. Algorithms that integrate electronic health records, biomarker results, imaging features, speech patterns, gait metrics, and cognitive data can help identify participants at defined disease stages and reduce heterogeneity. AI-supported imaging analysis is improving quantification of brain atrophy, amyloid and tau burden, dopaminergic pathway changes, and white matter integrity. Digital phenotyping through smartphones and wearables is also enabling more continuous measurement of tremor, bradykinesia, gait, sleep disruption, speech changes, and cognitive fluctuation, potentially reducing reliance on infrequent clinic-based assessments.

The cumulative impact of AI also extends to post-approval safety, adherence, and real-world evidence. Neurodegenerative drugs may carry complex monitoring needs, including imaging surveillance, laboratory testing, drug interaction assessment, and adverse event detection. AI-enabled pharmacovigilance can identify safety signals across claims, registries, clinical notes, and patient-reported data when appropriate governance is in place. However, adoption depends on validated models, transparent performance metrics, representative datasets, privacy safeguards, clinical oversight, and regulatory acceptance. AI is not replacing clinical judgment in neurology; it is increasingly functioning as an evidence accelerator that improves precision, efficiency, and continuity of care.

Key Regional Insights Across Global Neurodegenerative Drug Adoption

In Asia-Pacific, neurodegenerative drug activity is influenced by rapid population aging, expanding neurology infrastructure, and growing investment in dementia and movement disorder care. Japan, China, South Korea, India, and Australia are central to regional progress, with increasing use of biomarker diagnostics, clinical trial participation, and public health initiatives addressing dementia. Japan's super-aged population has created strong demand for Alzheimer's and Parkinson's disease care pathways, while China's large patient base and expanding hospital research networks are supporting broader clinical development. India is strengthening neurological care access but continues to face diagnostic gaps, affordability constraints, and uneven specialty distribution.

North America remains a leading region for neurodegenerative drug innovation due to established clinical trial networks, advanced imaging and biomarker capabilities, specialized neurology centers, and mature regulatory pathways for expedited review where serious unmet need exists. The United States has been central to Alzheimer's disease-modifying therapy implementation, real-world evidence generation, and biomarker-guided treatment decisions, while Canada contributes through academic research networks, universal care frameworks, and increasing focus on dementia strategies and rare neurological disorders.

Latin America is characterized by rising recognition of dementia, Parkinson's disease, and other neurodegenerative conditions, alongside persistent disparities in specialist access and advanced diagnostics. Brazil and Mexico are particularly important due to their large populations, growing clinical research participation, and public health interest in aging-related neurological disorders. Access to high-complexity biologics, genetic testing, PET imaging, and specialized infusion services remains uneven, making affordability and healthcare infrastructure decisive factors for therapy uptake.

Europe benefits from strong neurological research institutions, cross-border scientific collaboration, national dementia plans, health technology assessment systems, and established pharmacovigilance infrastructure. Western European countries tend to have broader access to specialized diagnostics and multidisciplinary neurology care, while parts of Central and Eastern Europe face more constrained access to advanced imaging, biomarker testing, and innovative therapies. European systems place strong emphasis on comparative effectiveness, safety monitoring, and cost-effectiveness evidence before broad reimbursement.

The Middle East is advancing through investments in specialty hospitals, genomic medicine, and tertiary care services, particularly in Gulf countries. Rising awareness of dementia and Parkinson's disease is increasing demand for neurology services, although access varies widely across the region. Genetic counseling and consanguinity-related rare neurological disease considerations are particularly relevant in some populations, supporting interest in precision medicine and inherited neurodegenerative disorder diagnostics.

Africa faces a growing but underdiagnosed neurodegenerative disease burden as life expectancy rises and noncommunicable disease surveillance improves. Many countries experience shortages of neurologists, limited access to neuroimaging, restricted biomarker testing, and low public awareness of dementia and movement disorders. However, regional progress in academic neurology, community health models, and global research collaborations is creating opportunities to improve diagnosis, registry development, and equitable access to essential neurological medicines.

Key Group Insights Shaping Neurodegenerative Drug Priorities

ASEAN countries are increasingly prioritizing healthy aging, dementia awareness, and noncommunicable disease capacity building, but the neurodegenerative drugs environment remains highly diverse. Singapore and Thailand have comparatively more developed specialty neurology services and research infrastructure, while Indonesia, Vietnam, the Philippines, and other ASEAN members face greater access barriers related to specialist density, diagnostic availability, and out-of-pocket costs. Regional progress depends on scalable cognitive screening, referral pathways, and affordability frameworks.

The GCC is strengthening its position through investment in advanced hospitals, genomic screening initiatives, digital health infrastructure, and specialty care hubs. Neurodegenerative drug access is supported by high healthcare spending in several member states, but long-term adoption depends on building memory clinics, movement disorder programs, trained neurologists, imaging capacity, and pharmacovigilance systems. The GCC's interest in precision medicine is especially relevant for rare inherited neurodegenerative conditions and population-specific genetic research.

The European Union provides a highly structured environment for neurodegenerative drug assessment through centralized regulatory review, national reimbursement decisions, health technology assessment coordination, and strong post-marketing safety systems. EU countries support extensive research in Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis-related neurodegeneration, and rare neurological disorders. However, differences in national reimbursement, diagnostic capacity, and specialist access can create variation in the timing and breadth of patient access after authorization.

BRICS economies represent a major strategic grouping due to large patient populations, expanding biomedical research capabilities, and growing government attention to aging and chronic disease. China and India are particularly influential because of demographic scale and increasing clinical trial activity, while Brazil and South Africa play important roles in regional access and research development. Russia maintains scientific and clinical interest in neurology, though broader geopolitical and regulatory factors can affect collaboration and medicine availability.

G7 countries have substantial influence on neurodegenerative drug development because they combine advanced research ecosystems, regulatory experience, high diagnostic sophistication, and major public funding for neurological disease research. The United States, Japan, Germany, France, the United Kingdom, Italy, and Canada are central to evidence generation, clinical guideline development, and reimbursement debate. Their policy decisions often shape global expectations for biomarker validation, clinical meaningfulness, safety management, and real-world data requirements.

NATO member countries collectively include many high-income healthcare systems with advanced neurology capabilities, but the grouping is not primarily a health policy bloc. Within NATO countries, neurodegenerative drug adoption is shaped by national regulatory alignment, reimbursement frameworks, defense-related brain health research, veteran neurological care, and cross-border scientific collaboration. Traumatic brain injury, neuropsychiatric comorbidity, and long-term neurological monitoring in military and veteran populations can add specific relevance to neurodegeneration research priorities.

Key Country Insights for Neurodegenerative Drug Development and Access

The United States is a core driver of neurodegenerative drug development through advanced clinical trial networks, biomarker infrastructure, patient registries, and regulatory mechanisms that support expedited pathways for serious diseases with unmet need. Implementation of disease-modifying Alzheimer's therapies has highlighted the importance of early diagnosis, amyloid confirmation, MRI monitoring, infusion capacity, and payer evidence requirements. Canada emphasizes national dementia planning, academic neurology research, and coordinated care, while access decisions are shaped by public reimbursement processes and provincial healthcare structures. Mexico is seeing rising demand for dementia and Parkinson's disease care, although specialist availability, diagnostic imaging access, and affordability continue to influence patient pathways.

Brazil is a major Latin American hub for neurological research and clinical care, with increasing attention to dementia, Parkinson's disease, ALS, and multiple sclerosis. Public and private sector differences affect access to advanced therapies and diagnostics. The United Kingdom benefits from strong neuroscience research, dementia policy initiatives, genetic medicine programs, and structured health technology assessment, making clinical effectiveness and value evidence central to adoption. Germany has extensive neurology infrastructure, advanced diagnostics, and strong clinical research capabilities, while France combines national health coverage, neuroscience research networks, and growing emphasis on early dementia diagnosis. Russia has a substantial neurology patient base and clinical expertise, but access to advanced neurodegenerative therapies can be affected by regulatory, procurement, and geopolitical factors. Italy and Spain have strong academic neurology communities, aging populations, and active dementia and movement disorder care pathways, though regional healthcare variation can influence diagnostic and treatment access.

China is expanding rapidly in neurodegenerative disease research, clinical trial capacity, hospital-based specialty care, and biomarker adoption, supported by the country's large aging population and increasing focus on brain health. India has a substantial unmet need in dementia, Parkinson's disease, and motor neuron disease care, with opportunities centered on low-cost diagnostics, tele-neurology, physician education, and broader access to essential and advanced medicines. Japan is among the most important countries for neurodegenerative drugs because of its advanced aging profile, established neurology expertise, and strong focus on Alzheimer's disease, Parkinson's disease, and regenerative medicine research. Australia contributes through high-quality clinical research, dementia care frameworks, and population health initiatives, with geography making telehealth and distributed care models important. South Korea is advancing through biomedical innovation, digital health capabilities, aging-related healthcare investment, and increasing clinical research participation in central nervous system disorders.

Actionable Recommendations for Neurodegenerative Drug Industry Leaders

Industry leaders should prioritize biomarker-enabled development strategies that align target biology, patient selection, endpoint design, and regulatory expectations from the earliest stages of research. For Alzheimer's disease and Parkinson's disease, this means integrating validated imaging, fluid biomarkers, genetic markers, and digital measures where scientifically appropriate. For ALS, Huntington's disease, and rare neurogenetic disorders, mutation-specific screening, natural history datasets, and patient registry partnerships should be central to trial readiness.

Organizations should also invest in access infrastructure before product launch. Disease-modifying neurodegenerative therapies often require diagnostic confirmation, specialist consultation, infusion or complex administration, safety imaging, laboratory monitoring, and caregiver support. Early collaboration with neurologists, radiologists, laboratory networks, payers, patient organizations, and health systems can reduce bottlenecks and support responsible adoption. Evidence packages should include clinical outcomes, biomarker rationale, quality-of-life measures, caregiver burden data, health resource utilization, and real-world safety plans.

To strengthen competitive positioning without relying on promotional claims, leaders should focus on transparent evidence generation, inclusive trial enrollment, decentralized participation options, and long-term pharmacovigilance. AI and digital health tools should be implemented with validation, bias assessment, data security, and clinician oversight. Finally, developers and healthcare stakeholders should prepare differentiated strategies for high-income markets, emerging economies, and under-resourced settings, recognizing that diagnosis capacity and affordability are as important as therapeutic innovation.

Research Methodology for Evidence-Based Neurodegenerative Drug Analysis

A robust research methodology for neurodegenerative drugs should combine primary and secondary research, clinical evidence review, regulatory analysis, and healthcare infrastructure assessment. Secondary research includes peer-reviewed medical literature, clinical trial registries, regulatory agency documents, treatment guidelines, health technology assessment reports, pharmacovigilance communications, epidemiological sources, and public health policy publications. Primary research may include structured discussions with neurologists, geriatricians, psychiatrists, radiologists, laboratory medicine specialists, payers, clinical trial investigators, patient advocacy representatives, and healthcare administrators.

The methodology should evaluate drug classes and mechanisms across symptomatic therapies, disease-modifying biologics, small molecules, RNA-based therapies, gene-targeted approaches, neuroprotective agents, and supportive treatments. It should also assess disease areas including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, multiple sclerosis-associated neurodegeneration, frontotemporal dementia, and rare inherited disorders. Key evidence dimensions include mechanism of action, clinical trial phase and design, biomarker use, endpoint selection, safety profile, administration requirements, monitoring burden, real-world evidence, regulatory status, and access considerations.

Data validation should rely on triangulation across clinical publications, regulatory filings, expert input, and healthcare system evidence. Because this field evolves rapidly, methodology must include systematic update protocols for trial readouts, label changes, safety warnings, diagnostic guideline updates, and reimbursement decisions. Strict separation between verified evidence and assumptions is essential, and analysis should avoid unsupported projections, promotional interpretation, or unverified commercial claims.

Conclusion: Advancing Evidence-Led Neurodegenerative Drug Innovation

Neurodegenerative drugs are progressing from symptom-focused management toward targeted, biomarker-supported, and potentially disease-modifying care. Scientific advances in protein aggregation, neuroinflammation, genetics, synaptic biology, and digital phenotyping are expanding therapeutic opportunities, while AI is improving discovery, trial design, diagnosis, and real-world monitoring. However, the field's success depends on more than therapeutic efficacy alone; it requires reliable early diagnosis, equitable biomarker access, trained specialist networks, payer confidence, caregiver support, and rigorous long-term safety surveillance.

Regional and country-level differences in neurology infrastructure, reimbursement, diagnostic capacity, and public health priorities will strongly influence how neurodegenerative drugs reach patients. High-income markets are likely to lead in complex therapy implementation, while emerging regions require scalable models that address affordability and specialist shortages. Industry leaders that combine scientific rigor with operational readiness, inclusive evidence generation, and responsible AI adoption will be best positioned to improve outcomes in Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other debilitating neurological disorders.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurodegenerative Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Cholinesterase Inhibitors
  • 7.2.1. Donepezil
  • 7.2.2. Pyridostigmine
  • 7.2.3. Rivastigmine
• 7.3. Decarboxylase Inhibitors
  • 7.3.1. Benserazide
  • 7.3.2. Carbidopa
  • 7.3.3. Methyldopa
• 7.4. Dopamine Agonist
  • 7.4.1. Apomorphine
  • 7.4.2. Cabergoline
  • 7.4.3. Pramipexole
  • 7.4.4. Rotigotine
• 7.5. Immunomodulators

8. Neurodegenerative Drugs Market, by Mode Of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral
• 8.4. Transdermal Patch

9. Neurodegenerative Drugs Market, by Mechanism Of Action

• 9.1. Introduction
• 9.2. Ion Channel Modulators
  • 9.2.1. Potassium Channel Modulators
  • 9.2.2. Sodium Channel Modulators
• 9.3. Synaptic Modulators

10. Neurodegenerative Drugs Market, by Therapeutic Type

• 10.1. Introduction
• 10.2. Neuroprotection
  • 10.2.1. Anti-Inflammatory Agents
  • 10.2.2. Antioxidants
• 10.3. Preventive Treatment
• 10.4. Symptomatic Treatment

11. Neurodegenerative Drugs Market, by Indication Type

• 11.1. Introduction
• 11.2. Alzheimer's Disease
• 11.3. Amyotrophic Lateral Sclerosis (ALS)
• 11.4. Multiple Sclerosis
  • 11.4.1. Primary Progressive
  • 11.4.2. Relapsing-Remitting
• 11.5. Parkinson's Disease

12. Neurodegenerative Drugs Market, by Sales Channel

• 12.1. Introduction
• 12.2. Offline
  • 12.2.1. Hospitals Pharmacies
  • 12.2.2. Retail Pharmacies
• 12.3. Online

13. Neurodegenerative Drugs Market, by End User

• 13.1. Introduction
• 13.2. Clinics
• 13.3. Contract Research Organizations
• 13.4. Hospitals
• 13.5. Research Institutes

14. Neurodegenerative Drugs Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Neurodegenerative Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Neurodegenerative Drugs Market, by Country

• 16.1. United States
• 16.2. Germany
• 16.3. China
• 16.4. United Kingdom
• 16.5. India
• 16.6. Japan
• 16.7. Russia
• 16.8. Brazil
• 16.9. Canada
• 16.10. Italy
• 16.11. Mexico
• 16.12. France
• 16.13. Spain
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. AbbVie Inc
• 18.2. AC Immune SA
• 18.3. Acadia Pharmaceuticals Inc
• 18.4. Alnylam Pharmaceuticals Inc
• 18.5. Alzheon Inc
• 18.6. Amneal Pharmaceuticals Inc
• 18.7. Amylyx Pharmaceuticals Inc
• 18.8. AstraZeneca PLC
• 18.9. Bayer AG
• 18.10. BioArctic AB
• 18.11. Biogen Inc
• 18.12. Bristol Myers Squibb Co
• 18.13. Cassava Sciences Inc
• 18.14. Denali Therapeutics Inc
• 18.15. Eisai Co Ltd
• 18.16. Eli Lilly and Company
• 18.17. Ionis Pharmaceuticals Inc
• 18.18. Lundbeck AS
• 18.19. Merck Co Inc
• 18.20. Neuren Pharmaceuticals
• 18.21. Neurocrine Biosciences Inc
• 18.22. Novartis AG
• 18.23. Orion Pharma
• 18.24. Pfizer Inc
• 18.25. Sage Therapeutics Inc
• 18.26. Sanofi SA
• 18.27. Takeda Pharmaceutical Company Limited
• 18.28. Teva Pharmaceutical Industries Ltd
• 18.29. UCB SA
• 18.30. Voyager Therapeutics Inc